To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.
Standard of care in patients with advanced ovarian cancer is primary cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy and interval cytoreductive surgery is an alternative in selected patients. Most data exist with interval cytoreductive surgery following 3-4 cycles of chemotherapy, however, some patients experience a delay. So far, the impact of delayed cytoreductive surgery (following \>5 cycles of chemotherapy) on patient outcomes is poorly defined. There is also a paucity of data in women who undergo no surgery (\>5 cycles of chemotherapy alone) and factors influencing international discrepancies in access to cytoreductive surgery.
Study Type
OBSERVATIONAL
Enrollment
800
cytoreductive surgery after 3-4 cycles of chemotherapy
surgery after \>5 cycles of chemotherapy
no cytoreductive surgery (\>5 cycles of chemotherapy alone)
The Royal London Hospital
London, United Kingdom
RECRUITINGoverall survival
defined from date of diagnosis to date of death by any cause or loss to follow-up
Time frame: 15 years
progression free survival
defined from date of diagnosis to date of first recurrence
Time frame: 15 years
facilitator/barriers to access to cytoreductive surgery
topic guide interview questionnaire to be used to elicit factors aiding/preventing access to cytoreductive surgery internationally
Time frame: 15 years
Post-operative morbidity
as per Clavien-Dindo classification
Time frame: within 30 days from date of surgery
Resectability rates
R0 = no visible disease, R1 = \<10mm visible residual disease, R2 = \>10mm visible residual disease
Time frame: at time of surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.